Skip to content
Research Article Open access CC BY 4.0

Chronic Total Occlusion of Coronary Left Main Artery Supplied by Right Collaterals under Vascular Endothelial Growth Factor Inhibitor Therapy

K. Chawki, E. M. Rochd, M. Selmaoui, A. El Jazouli, M. HABOUB, S. AROUS, G. Bennouna, A. DRIGHIL, R. HABBAL

Asian Journal of Cardiology Research · pp. 328–332 · Published 18 Aug 2023

Abstract

We report a rare case of a patient who despite being under anti VEGF : Bevacizumab , developed a large coronary collateral circulation completely supplying the chronic total occlusion of left main coronary artery. Bevacizumab, a monoclonal antibody was the first potent angiogenic inhibitor , targeting vascular endothelial growth factor (VEGF)-A. Some of it's important cardiovascular adverse events include arterial and venous thrombotic events, coronary artery disease and heart failure resulting from inhibition of endothelial regeneration. Our patient developed dyspnea after 1 year of receiving bevacizumab with a chronic total occlusion of the left main coronary artery with the particularity of developing extensive collaterals despite the anti VEGF treatment she received.

Coronary artery disease vascular endothelial growth myocardial dysfunction Bevacizumab

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.